- Home
- AVTX vs CTOR Comparison
AVTX vs CTOR Comparison
Compare AVTX & CTOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVTX
- CTOR
- Stock Information
- Founded
- AVTX 2011
- CTOR 2021
- Country
- AVTX United States
- CTOR United States
- Employees
- AVTX N/A
- CTOR N/A
- Industry
- AVTX Biotechnology: Pharmaceutical Preparations
- CTOR
- Sector
- AVTX Health Care
- CTOR
- Exchange
- AVTX Nasdaq
- CTOR NYSE
- Market Cap
- AVTX 57.4M
- CTOR 52.2M
- IPO Year
- AVTX 2015
- CTOR N/A
- Fundamental
- Price
- AVTX $4.25
- CTOR $0.87
- Analyst Decision
- AVTX Strong Buy
- CTOR Strong Buy
- Analyst Count
- AVTX 6
- CTOR 2
- Target Price
- AVTX $34.20
- CTOR $4.50
- AVG Volume (30 Days)
- AVTX 66.4K
- CTOR 65.0K
- Earning Date
- AVTX 05-20-2025
- CTOR 05-21-2025
- Dividend Yield
- AVTX N/A
- CTOR N/A
- EPS Growth
- AVTX N/A
- CTOR N/A
- EPS
- AVTX N/A
- CTOR N/A
- Revenue
- AVTX $441,000.00
- CTOR N/A
- Revenue This Year
- AVTX N/A
- CTOR N/A
- Revenue Next Year
- AVTX N/A
- CTOR N/A
- P/E Ratio
- AVTX N/A
- CTOR N/A
- Revenue Growth
- AVTX N/A
- CTOR N/A
- 52 Week Low
- AVTX $4.15
- CTOR $0.55
- 52 Week High
- AVTX $16.00
- CTOR $49.00
- Technical
- Relative Strength Index (RSI)
- AVTX 31.02
- CTOR N/A
- Support Level
- AVTX $4.80
- CTOR N/A
- Resistance Level
- AVTX $5.26
- CTOR N/A
- Average True Range (ATR)
- AVTX 0.45
- CTOR 0.00
- MACD
- AVTX 0.03
- CTOR 0.00
- Stochastic Oscillator
- AVTX 11.96
- CTOR 0.00
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
About CTOR CITIUS ONCOLOGY INC
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.